Brief: Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP)
14/06/2023 11:53
June 14 (Reuters) - Eagle Pharmaceuticals Inc EGRX.O :
* EAGLE PHARMACEUTICALS RECEIVES FDA QUALIFIED INFECTIOUS
DISEASE
PRODUCT (QIDP) AND FAST-TRACK DESIGNATION FOR CAL02, PROVIDING
FIVE-YEAR EXCLUSIVITY EXTENSION
* EAGLE PHARMACEUTICALS RECEIVES FDA QUALIFIED INFECTIOUS
DISEASE
PRODUCT (QIDP) AND FAST-TRACK DESIGNATION FOR CAL02, PROVIDING
FIVE-YEAR EXCLUSIVITY EXTENSION
* EAGLE PHARMACEUTICALS INC: EAGLE MAY QUALIFY FOR UP TO
FIVE
ADDITIONAL YEARS OF PATENT TERM EXCLUSIVITY, UP TO 2040
* EAGLE PHARMACEUTICALS INC - BELIEVES THAT CAL02 COULD ALSO
BE
ELIGIBLE FOR BREAKTHROUGH THERAPY DESIGNATION
* EAGLE PHARMACEUTICALS:PHASE 2 CLINICAL STUDY UNDERWAY TO
ASSESS
EFFICACY, SAFETY OF CAL02 ADMINISTERED INTRAVENOUSLY WITH CARE
IN PATIENTS WITH SCABP
Source text for Eikon: ID:nGNX8rnLz7
Further company coverage: EGRX.O
Recent news on Eagle Pharmaceuticals
See all newsDoes a common heart attack pill help everyone? Studies disagree
Brief: Eagle Pharmaceuticals Says Continuing To Evaluate Its Internal Control Over Financial Reporting
Brief: Nantahala Capital Management, Llc Reports 15.1% Passive Stake In Eagle Pharmaceuticals Inc As Of June 30- SEC Filing
Brief: Eagle Pharmaceuticals Says On May 28, Co Requested Hearing Before Hearings Panel Of Nasdaq, Following Delisting Notice From Nasdaq - SEC Filing
Brief: Eagle Pharmaceuticals Announces Receipt Of Delisting Notification From Nasdaq